Medical Educational Resource
Myotonic Dystrophy (DM): Core features, clinical subtypes, and outcome assessments
Activity Snapshot
Faculty
Virginia Commonwealth University
This CE-accredited webinar focused on Myotonic Muscular Dystrophy (DM), featuring Nicholas E. Johnson, MD, MSCI, FAAN, of Virginia Commonwealth University, explores the potential for natural history studies and biomarkers to define reliable outcome measures in DM.
Upon completion of the educational activity, participants should be able to:
● Identify challenges in the diagnosis and management of myotonic dystrophy (DM).
● Describe the role of natural history studies and pathology in defining outcome measures for potential DM therapies.
● Guide patients to resources in DM to support ongoing care, including opportunities to participate in clinical studies.
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and MDA. AKH Inc., Advancing Knowledge in Healthcare is jointly
accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
See full accreditation and designation statements and disclosure report here.
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at wendi@akhcme.com.
Name Relationship Commercial Interest
Nicholas E. Johnson, MD, MSCI, FAAN: Consultant; Novartis, Sarepta, AskBio, Fulcrum, Vertex, Dyne, Arthex, Avidity, Pepgen, Rgenta, Denali, Kate Therapeutics, Juvena, Angle Therapeutics, Sanofi
Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer): N/A; Nothing to disclose
Dorothy Duffy, RPh (planner/reviewer): N/A; Nothing to disclose
Broc Pollinger, MSW, LSW, OSW-C, (planner/reviewer): N/A; Nothing to disclose
AKH Inc Staff and Planners: N/A; Nothing to disclose
MDA Staff and Planners: N/A; Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line
